LACTOBACILLUS COMPOSITION FOR INHIBITING GASTRITIS INDUCED BY GASTRIC HELICOBACTER PYLORI AND USE THEREOF

• US 20200077692A1
• Filed: 09/12/2018
• Published: 03/12/2020
• Est. Priority Date: 09/12/2018
• Status: Active Grant

• Current Assignee: GenMont Biotech Incorporation
• Original Assignee: GenMont Biotech Incorporation
• Inventors: Chen, Yi-Hsing, Tsai, Wan-Hua, Chen, Ya-Hui, Lai, Chih-Ho, Lin, Yu-Hsin
• Granted Patent: US 10,638,784 B2
• Time in Patent Office: Days
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/14 Yeasts or derivatives thereof
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A23V 2400/113 Acidophilus
• CPC Class Codes: A23V 2400/169 Plantarum
• CPC Class Codes: A23V 2400/175 Rhamnosus
• CPC Class Codes: A23V 2400/51 Bifidobacterium
• CPC Class Codes: A61K 2035/115 Probiotics
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention provides a pharmaceutical composition and a food product for inhibiting gastritis induced by gastric Helicobacter pylori, comprising Lactobacillus selected from a group composed of Lactobacillus rhamnosus GM-020 (also known as GMNL-74) with deposited number CCTCC M203098; Lactobacillus acidophilus GMNL-185 with deposited number CCTCC M2017764; and Lactobacillus plantarum GMNL-662 with deposited number CCTCC M2016571; and any two of the above bacteria.

Claims

1. A Lactobacillus acidophilus GMNL-185 for inhibiting gastritis induced by gastric Helicobacter pylori, the deposited numbers thereof being BCRC910774 and CCTCC M2017764.

2. A pharmaceutical composition for inhibiting gastritis induced by gastric Helicobacter pylori, comprising lactics selected from a group consisting of Lactobacillus rhamnosus GMNL-74, Lactobacillus acidophilus GMNL-185, Lactobacillus plantarum GMNL-662, and any two of the above bacteria.

3. The pharmaceutical composition as claimed in claim 2, wherein the deposited numbers of the Lactobacillus rhamnosus GMNL-74 are BCRC910236 and CCTCC M203098, the deposited numbers of the Lactobacillus acidophilus GMNL-185 are BCRC910774 and CCTCC M2017764, and the deposited numbers of the Lactobacillus plantarum GMNL-662 are BCRC910738 and CCTCC M2016571.

4. The pharmaceutical composition as claimed in claim 2, wherein the pharmaceutical composition is a dosage form for oral administration.

5. The pharmaceutical composition as claimed in claim 4, wherein the dosage form is selected from a group consisting of solution, suspension, emulsion, powder, pastille, pellet, syrup, troche, tablet, chewing gum, jatex and capsule.

6. The pharmaceutical composition as claimed in claim 2, wherein the pharmaceutical composition can further comprise pharmaceutically acceptable carrier, vehicle and thinner.

7. The pharmaceutical composition as claimed in claim 2, wherein the lactics comprise a culture solution of one of surface substances of the bacteria and secretory substances of the bacteria, or a combination of both.

8. The pharmaceutical composition as claimed in claim 2, wherein the lactics are dead bacteria or live bacteria.

9. A food product, comprising lactics and an edible material, wherein the lactics are selected from a group composed of Lactobacillus rhamnosus GMNL-74, Lactobacillus acidophilus GMNL-185, Lactobacillus plantarum GMNL-662, and any two of the above bacteria.

10. The food product as claimed in claim 9, wherein the deposited numbers of the Lactobacillus rhamnosus GMNL-74 are BCRC910236 and CCTCC M203098, the deposited numbers of the Lactobacillus acidophilus GMNL-185 are BCRC910774 and CCTCC M2017764, and the deposited numbers of the Lactobacillus plantarum GMNL-662 are BCRC910738 and CCTCC M2016571.

11. The food product as claimed in claim 9, can further comprising at least one type of lactics selected from the following group consisting of:

Lactobacillus sp., Bifidobacterium, Streptococcus sp. and yeasts.

12. The food product as claimed in claim 9, wherein the edible material is selected from a group composed of water, fluid milk products, concentrated milk, yogurt, sour milk, frozen yogurt, lactic acid bacteria-fermented beverages, milk powder, ice cream, cream cheeses, hard cheeses, soy milk, fermented soy milk, vegetable-fruit juices, juices, sports drinks, confectionery, jelly, candies, infant foods, health foods, animal feeds, Chinese medicinal herbs compositions and dietary supplements.

13. The food product as claimed in claim 9, wherein the lactics comprise a culture solution of one of surface substances of the bacteria and secretory substances of the bacteria, or a combination of both.

14. The food product as claimed in claim 9, wherein the lactics are dead bacteria or live bacteria.

15. A method for inhibiting gastritis induced by gastric Helicobacter pylori, comprising administering a therapeutically effective amount of a Lactobacillus composition, wherein the Lactobacillus composition is selected from a group composed of Lactobacillus rhamnosus GM-020 (also known as GMNL-74), Lactobacillus acidophilus GMNL-185, and Lactobacillus plantarum GMNL-662;

wherein the deposited numbers of the Lactobacillus rhamnosus GM-020 are BCRC910236 and CCTCC M203098, the deposited numbers of the Lactobacillus acidophilus GMNL-185 are BCRC910774 and CCTCC M2017764, and the deposited numbers of the Lactobacillus plantarum GMNL-662 are BCRC910738 and CCTCC M2016571.

16. The method as claimed in claim 15, wherein the therapeutically effective amount is 10⁶˜

10⁸ CFU per time.

17. The method as claimed in claim 15, wherein the Lactobacillus composition achieve the efficacy of inhibiting gastritis induced by gastric Helicobacter pylori by inhibiting the gastric Helicobacter pylori adhesion or invasion of gastric epithelial cells.

18. The method as claimed in claim 15, wherein the Lactobacillus composition can further inhibit the gastric Helicobacter pylori-induced interleukine-8 (IL-8) and transcription factor NF-κ

B.

19. The method as claimed in claim 15, wherein the Lactobacillus composition can further inhibit the gastric COX-2 protein expression.

20. The method as claimed in claim 15, wherein the Lactobacillus composition comprise a culture solution of one of surface substances of the bacteria and secretory substances of the bacteria, or a combination of both.

21. The method as claimed in claim 15, wherein the Lactobacillus composition are dead bacteria or live bacteria.

22. The method as claimed in claim 15, wherein the gastric Helicobacter pylori are multidrug-resistant Helicobacter pylori strains or antibiotic-sensitive Helicobacter pylori strains.